Dermatology

A 6-month text-messaging programme improved cardiovascular risk self-management in adults with psoriasis in a randomised trial.

Combining ixekizumab with tirzepatide improved skin clearance and weight loss in adults with psoriasis and obesity in a Phase 3b trial.

New trial data show dupilumab improves itch, skin healing and quality of life in patients with prurigo nodularis, even without optimal response.

English registry data show lentigo maligna has only a 1% risk of progression to invasive melanoma over 10 years.

Tildrakizumab showed sustained efficacy and safety in moderate-to-severe scalp psoriasis, regardless of obesity status, over 52 weeks.

A real-world study found tildrakizumab improved skin clearance, symptoms, and quality of life in adults with plaque psoriasis.

A large BADBIR study assesses serious infection risk across psoriasis systemic treatments, highlighting largely similar safety profiles with some treatment-specific signals.

High-potency and long-term topical corticosteroid use may increase type 2 diabetes risk, according to a large nationwide cohort study.

COVID-19 disrupted melanoma diagnoses, reducing early detection and shifting prognostic patterns across regions with different public health strategies.

Narrowband and broadband UVB show similar efficacy in atopic dermatitis, but narrowband therapy is better tolerated, a randomised trial finds.

The systemic effects of sunlight may include lower mortality and reduced disease burden, according to a decade-long review.

Ultrasound and CT improve nodal staging in high-risk cSCC but show reduced accuracy in immunosuppressed patients. Learn more about diagnostic strategies.

New research identifies PA2G4 as a key driver of keratinocyte proliferation and survival in psoriasis, offering a potential new therapeutic target.

Pirfenidone exosomes improve wound healing and reduce scarring in preclinical models. Discover this innovative antifibrotic therapy. Read more.

A Japanese study highlights poorer outcomes in paranasal mucosal melanoma and identifies neutrophil–lymphocyte ratio as a key prognostic biomarker.

A major cohort study finds no meaningful link between atopic dermatitis and poorer academic performance in adolescents.

Dupilumab significantly improves disease severity and lesion healing in prurigo nodularis, according to pooled Phase III trial data.

Study introduces a clinical score to predict laryngeal involvement in pemphigus vulgaris, supporting targeted use of laryngoscopy.

Patients with chronic lymphocytic leukemia face nearly double the risk of skin cancer, with increased metastasis and mortality, a large cohort study finds.

A European study shows photopatch testing with longer occlusion improves detection of sunscreen and NSAID photoallergies.

Meta-analysis shows AI-assisted melanoma diagnosis performs similarly to dermatologists, though further validation is needed for routine clinical use.

A real-world study shows delgocitinib matches PUVA effectiveness in chronic hand eczema, with trends toward improved quality of life.

Longer antibiotic courses for acne raise recurrence and resistance risk without improving short-term outcomes, new real-world data show.

A phase 2 trial shows promising results for hidradenitis suppurativa treatment, offering hope for patients with limited options after anti TNF therapy failure.

Liposomal retinol and niacinamide improve stability, skin penetration, and anti-aging effects, offering promise for advanced skincare formulations.

Patients with rosacea may face a higher risk of depression, according to a large Korean cohort study highlighting the need for integrated care.

The MEL-SELF trial reveals gaps in melanoma self-examination practices, highlighting patient confidence and psychological factors affecting early detection.

LAG-3 and TIGIT expression may predict skin melanoma progression and survival. Discover how these immune markers could shape future therapies. Read more.

Most early responders with atopic dermatitis sustain minimal disease activity at one year, with baseline factors predicting long-term control.

Three-year BE RADIANT results highlight durable bimekizumab benefits in plaque psoriasis, improving PROs and QoL. Read more.

A randomised placebo-controlled study shows silicone gel significantly improves scar quality in head and neck wounds without adverse effects.

Major depressive disorder shares a Th2 immune signature with atopic dermatitis, highlighting dupilumab as a potential targeted therapy.

A long-term cohort study shows molecular diagnostics can distinguish hand eczema from psoriasis, improving treatment decisions and patient quality of life.

Stopping washcloth use during bathing may significantly reduce chronic itch, according to a new observational dermatology study exploring simple lifestyle changes.

A study of nearly 12,000 adults links sedentary behaviour, late sleep and psychological distress to higher adult acne risk, while regular exercise shows protective benefits.

New research identifies a tRNA-derived RNA fragment that protects skin from UV-induced photoageing by preserving collagen and stabilising key mRNAs.

Global analysis finds people with atopic dermatitis have significantly higher rates of asthma and rhinitis, highlighting the need for integrated respiratory screening.

Sunscreen use may prevent UV-induced gene and epigenetic changes, helping maintain pathways linked to healthy skin, according to new molecular profiling research.

A phase IIb trial demonstrates that topical pumecitinib 3% gel significantly improves mild-to-moderate atopic dermatitis, with twice-daily dosing showing superior efficacy.

A cohort study shows mycophenolate mofetil and methotrexate reduce disease activity in juvenile localised scleroderma, with fewer adverse effects seen with MMF.

A 52-week study shows risankizumab improves both visible psoriasis and underlying vascular inflammation, with OCT revealing sustained subclinical skin changes.

A nationwide Dutch study reports treatment patterns, upstaging rates, and long-term recurrence outcomes in patients with lentigo maligna.

Acne risk rises sharply in transmasculine individuals starting testosterone and also affects transfeminine patients on estradiol. Read more.

Real-world data from Italy show high two-year drug survival and sustained disease control with bimekizumab in moderate-to-severe plaque psoriasis.

A birth cohort study reveals how genetics, environment, and hygiene shape the infant skin microbiome and its early links to atopic dermatitis.

Real-world registry data from Germany show apremilast improves psoriasis severity and quality of life, with a safety profile consistent with clinical trials.

Real-world data suggest lebrikizumab delivers sustained clinical and quality-of-life improvements in patients with moderate-to-severe atopic dermatitis.

Lower dietary antioxidant intake is linked to higher oxidative stress in rosacea, with potential implications for disease severity and clinical management.

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and bioexperienced patients.

Adjunctive vitamin D may improve pain, healing, and inflammation in oral lichen planus, with benefits most evident during the first six weeks of treatment.

Spatial proteomics analysis shows tertiary lymphoid structures correlate with immunotherapy response and survival in Merkel cell carcinoma.

A large Mendelian randomisation study reveals that higher BMI and IBD causally increase hidradenitis suppurativa risk, providing actionable insights for dermatologists and patient counselling.

Adjunctive NB-UVB phototherapy improved disease control in chronic plaque psoriasis patients with secondary loss of response to adalimumab.

Genetic analysis shows higher BMI increases hidradenitis suppurativa risk, while smoking evidence is inconclusive. The study also supports a causal link with IBD.

Vixarelimab significantly reduced itch severity and improved skin clearance in patients with prurigo nodularis in a phase 2b randomized clinical trial.

New epidemiological data reveal long serial intervals and sustained scabies transmission in Europe, highlighting how modest prevention could curb epidemic growth.